MINNEAPOLIS/ST. PAUL - February 19, 2015 – A new comprehensive analysis from the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, involving leading International Ebola researchers, examines what is known about transmission of the Ebola virus and cautions that the public health community should not rule out the possibility of respiratory transmission. Prior to the current Ebola epidemic in West Africa there have been only 24 reported Ebola outbreaks with approximately 2,400 cases reported over the previous 39 years. Evidence suggests that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission, however, this evidence is based on a limited number of studies.
WASHINGTON, DC – February 17, 2015 - The typical Escherichia coli, the laboratory rat of microbiology, is a tiny 1-2 thousandths of a millimeter long. Now, by blocking cell division, two researchers at Concordia University in Montreal have grown E. coli that stretch three quarters of a millimeter. That’s up to 750 times their normal length. The research has potential applications in nanoscale industry, and may lead to a better understanding of how pathogens work. The study is published ahead of print on February 17 in the Journal of Bacteriology, a journal of the American Society for Microbiology.
WASHINGTON, DC - FEBRUARY 11, 2015 -- With minor tinkering, a peptide—a tiny protein—from the skin of a frog could be fashioned into a novel antibiotic that would lack the toxic byproducts of some more conventional drugs. More importantly, such peptides would represent a new class of antibiotics, at a time when new classes are sorely needed as resistance rises among existing classes. The research was published online, 26 January 2015, in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
Washington, DC - February 13, 2015 - According to a multinational clinical trial involving nearly 20,000 young women, the human papilloma virus vaccine, Cervarix, not only has the potential to prevent cervical cancer, but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18, which are responsible for about 70 percent of all cases. That effectiveness endured for the study’s entire follow-up, of up to four years. The research was published February 4 in Clinical and Vaccine Immunology, a journal of the American Society for Microbiology.